Case Report: Cryptococcal meningitis in Hodgkin’s Lymphoma patient receiving brentuximab-vedotin therapy [version 2; peer review: 2 approved]
Cryptococcus neoformans infections occur mostly in immunodeficient individuals, being the most common opportunistic fungal central nervous system (CNS) infection in HIV seropositive patients. Moreover, other conditions affecting host immunity, such as hematologic malignancies, organ transplantation...
Main Authors: | Tatiana Cunha Pereira, Rita Rb-Silva, Rita Félix Soares, Nelson Domingues, José Mariz |
---|---|
Format: | Article |
Language: | English |
Published: |
F1000 Research Ltd
2020-08-01
|
Series: | F1000Research |
Online Access: | https://f1000research.com/articles/9-687/v2 |
Similar Items
-
Brentuximab vedotin in pediatric Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01) -
Overall survival with brentuximab vedotin in advanced Hodgkin lymphoma
by: Shuvadeep Ganguly, et al.
Published: (2022-01-01) -
Brentuximab vedotin for relapsed or refractory Hodgkin’s lymphoma
by: Chen R, et al.
Published: (2015-03-01) -
Brentuximab vedotin is the first target drug in the treatment of hodgkin lymphoma
by: G. S. Tumyan
Published: (2018-11-01) -
Brentuximab vedotin in the treatment of relapsed and refractory forms of Hodgkin lymphoma
by: E A Demina
Published: (2016-06-01)